SG10201609131YA - Zinc-pga compositions and methods for treating cancer - Google Patents

Zinc-pga compositions and methods for treating cancer

Info

Publication number
SG10201609131YA
SG10201609131YA SG10201609131YA SG10201609131YA SG10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA SG 10201609131Y A SG10201609131Y A SG 10201609131YA
Authority
SG
Singapore
Prior art keywords
methods
tumors
compositions
zinc
tumor
Prior art date
Application number
SG10201609131YA
Inventor
Fred Chung Jinhyuk
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Priority to SG10201609131YA priority Critical patent/SG10201609131YA/en
Priority to KR1020197015744A priority patent/KR102616690B1/en
Priority to CA3042383A priority patent/CA3042383A1/en
Priority to MX2019005104A priority patent/MX2019005104A/en
Priority to SG11201903753QA priority patent/SG11201903753QA/en
Priority to AU2017354787A priority patent/AU2017354787B2/en
Priority to SG10202013112YA priority patent/SG10202013112YA/en
Priority to PCT/SG2017/050545 priority patent/WO2018084806A1/en
Priority to US16/346,286 priority patent/US11944640B2/en
Priority to JP2019545869A priority patent/JP7083835B2/en
Priority to EP17798014.1A priority patent/EP3534914A1/en
Priority to CN201711108631.5A priority patent/CN108014131B/en
Priority to CN202310311382.9A priority patent/CN116350658A/en
Publication of SG10201609131YA publication Critical patent/SG10201609131YA/en
Priority to MX2022011372A priority patent/MX2022011372A/en
Priority to JP2022089345A priority patent/JP7466822B2/en
Priority to AU2023203220A priority patent/AU2023203220A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

ZINC-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER The invention relates to pharmaceutical compositions comprising a zinc 2+ salt and a g -polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. An in vitro flow cytometric analysis of human cancer lines treated with one embodiment of a ZnPGA composition, Figure 2, demonstrate that the methods of the invention induce PARP1-mediated tumor necrosis, the method comprising administering a therapeutically effective amount of a Zn(II) salt and a g -polyglutamic acid carrier to the tumor. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors. Figure 2
SG10201609131YA 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer SG10201609131YA (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
PCT/SG2017/050545 WO2018084806A1 (en) 2016-11-01 2017-10-31 ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER
US16/346,286 US11944640B2 (en) 2016-11-01 2017-10-31 Zinc-[gamma]-PGA compositions and methods for treating cancer
MX2019005104A MX2019005104A (en) 2016-11-01 2017-10-31 Zinc-y-pga compositions and methods for treating cancer.
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer
AU2017354787A AU2017354787B2 (en) 2016-11-01 2017-10-31 Zinc-gamma-PGA compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer
KR1020197015744A KR102616690B1 (en) 2016-11-01 2017-10-31 Zinc-γ-PGA compositions and methods for treating cancer
CA3042383A CA3042383A1 (en) 2016-11-01 2017-10-31 Zinc-.gamma.-pga compositions and methods for treating cancer
JP2019545869A JP7083835B2 (en) 2016-11-01 2017-10-31 Zinc-γ-PGA composition and methods for treating cancer
EP17798014.1A EP3534914A1 (en) 2016-11-01 2017-10-31 Zinc- -pga compositions and methods for treating cancer
CN201711108631.5A CN108014131B (en) 2016-11-01 2017-11-01 Zinc-gamma-PGA compositions and methods for treating cancer
CN202310311382.9A CN116350658A (en) 2016-11-01 2017-11-01 Zinc-gamma-PGA compositions and methods of treating cancer
MX2022011372A MX2022011372A (en) 2016-11-01 2019-04-30 Zinc-î³-pga compositions and methods for treating cancer.
JP2022089345A JP7466822B2 (en) 2016-11-01 2022-06-01 Zinc-γ-PGA Compositions and Methods for Treating Cancer - Patent application
AU2023203220A AU2023203220A1 (en) 2016-11-01 2023-05-23 Zinc-gamma-pga compositions and methods for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SG10201609131YA true SG10201609131YA (en) 2018-06-28

Family

ID=60327362

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer

Country Status (10)

Country Link
US (1) US11944640B2 (en)
EP (1) EP3534914A1 (en)
JP (2) JP7083835B2 (en)
KR (1) KR102616690B1 (en)
CN (2) CN116350658A (en)
AU (2) AU2017354787B2 (en)
CA (1) CA3042383A1 (en)
MX (2) MX2019005104A (en)
SG (3) SG10201609131YA (en)
WO (1) WO2018084806A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (en) * 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. Oncology treatment with zinc preparations
KR102094182B1 (en) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 water-soluble polyglutamic acid complex composition containing zinc

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (en) 1989-06-28 1998-02-16 味の素株式会社 Foods and drinks containing easily absorbable minerals
JP3551149B2 (en) 1992-03-24 2004-08-04 味の素株式会社 Easy-absorbable mineral-containing composition and food and drink containing it
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
DE69330595T2 (en) 1992-11-25 2002-05-23 Ajinomoto Kk Preparations and foods containing minerals and poly-gamma-glutamic acid
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ITMI950515A0 (en) 1995-03-16 1995-03-16 Valpharma Sa GASTRO-RESISTANT FORMULATIONS CONTAINING ZINC
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (en) 1998-05-06 1999-11-16 Yoshio Inoue Mineral (zinc) formulation for livestock gentle to stomach and its production
AU2291001A (en) 1999-12-23 2001-07-03 Emory University Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
AU2003232884A1 (en) 2002-01-25 2003-09-02 Emory University Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (en) 2003-07-10 2005-07-01 주식회사 바이오리더스 Composition for promoting an absorption of mineral in body comprising poly-gamma-glutamic acid having ultla high molecular weight
JP4457641B2 (en) 2003-11-10 2010-04-28 味の素株式会社 Gelatin capsule
JP5162812B2 (en) 2004-07-08 2013-03-13 大正製薬株式会社 Zinc-containing composition for oral administration
BRPI0613796A2 (en) 2005-06-07 2011-02-15 Univ Yale pharmaceutical compositions and their uses, and methods of treating cancer and other pathological conditions or conditions by the use of clevudine (lfmau) and telbivudine (ldt)
RU2008100017A (en) * 2005-06-10 2009-07-20 Бипар Сайенсиз, Инк. (Us) PARP MODULATORS AND CANCER TREATMENT METHOD
JPWO2007043606A1 (en) 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ Antidiabetic drug comprising an anionic polyamino acid / metal complex
US7528125B2 (en) 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
CN101674852A (en) 2007-04-10 2010-03-17 日东电工株式会社 Multi-functional polyglutamate drug carriers
JP2010526917A (en) 2007-05-09 2010-08-05 日東電工株式会社 Polyglutamate complex and polyglutamate-amino acid complex having plural kinds of drugs
WO2008140781A1 (en) 2007-05-09 2008-11-20 Atherogenics, Inc. Spiro compounds for treatment of inflammatory disorders
AU2009344184B2 (en) 2009-04-10 2016-05-12 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
JO3635B1 (en) 2009-05-18 2020-08-27 Millennium Pharm Inc Solid pharmaceutical compositions and processes for their production
CN101716180B (en) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 Combined medicament for supplementing zinc and calcium and preparation method thereof
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
CN103917231B (en) 2011-09-13 2016-09-28 药品循环有限责任公司 Combination formulations of histone deacetylase inhibitor and bendamustine and application thereof
BR112015011699B1 (en) 2012-11-21 2021-01-12 KBS Research, LLC herbal supplements and their uses
TWI660748B (en) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 Suspension for oral administration comprising amorphous tolvaptan
US9132098B2 (en) * 2013-03-28 2015-09-15 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
CA2909349C (en) * 2013-04-12 2023-01-03 Rebecca Lambert Bent Use of a multi-agent composition for treatment of cancer
EP2989115A4 (en) 2013-04-26 2017-01-11 Nitto Denko Corporation A large scale process for preparing poly (glutamyl-glutamate) conjugates
WO2015009699A1 (en) 2013-07-15 2015-01-22 Ketter Patrick Methods and compositions to prevent or treat bacterial infections
JP2016069303A (en) 2014-09-29 2016-05-09 タカラバイオ株式会社 Hair loss inhibiting composition containing fucoidan as active ingredient
ES2630106T3 (en) 2014-10-07 2017-08-18 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
JP6716464B2 (en) 2014-12-03 2020-07-01 ノーベルファーマ株式会社 Zinc acetate hydrate tablet and method for producing the same
EA201990530A1 (en) 2016-08-19 2019-07-31 БРУКЛИН ИММУНОТЕРАПЬЮТИКС ЭлЭлСи WAYS OF APPLICATION OF PD-1 / PD-L1 INHIBITORS AND / OR CTLA-4 INHIBITORS WITH A BIOLOGICAL PRODUCT CONTAINING SEVERAL CYTOKINE COMPONENTS FOR THE TREATMENT OF CANCER
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (en) 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. Oncology treatment with zinc preparations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Also Published As

Publication number Publication date
SG11201903753QA (en) 2019-05-30
CN116350658A (en) 2023-06-30
JP2022116255A (en) 2022-08-09
WO2018084806A1 (en) 2018-05-11
AU2017354787B2 (en) 2023-02-23
EP3534914A1 (en) 2019-09-11
KR102616690B1 (en) 2023-12-21
AU2023203220A1 (en) 2023-06-22
JP2019534330A (en) 2019-11-28
CN108014131A (en) 2018-05-11
AU2017354787A1 (en) 2019-05-16
KR20190120159A (en) 2019-10-23
CN108014131B (en) 2023-04-14
SG10202013112YA (en) 2021-02-25
JP7466822B2 (en) 2024-04-15
MX2022011372A (en) 2022-10-10
US20190255104A1 (en) 2019-08-22
MX2019005104A (en) 2019-10-30
US11944640B2 (en) 2024-04-02
CA3042383A1 (en) 2018-05-11
JP7083835B2 (en) 2022-06-13

Similar Documents

Publication Publication Date Title
SG10201609131YA (en) Zinc-pga compositions and methods for treating cancer
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2021008610A (en) Cancer treatment using combinations of erk and raf inhibitors.
MX2016007351A (en) Combination therapy for treating cancer.
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2019010601A (en) Combination therapy for treating cancer.
MX2018003331A (en) Administration of deuterated cftr potentiators.
MX2019013701A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents.
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
MX347225B (en) Methods of treatment of pancreatic cancer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2018007823A (en) Bromodomain and extra-terminal protein inhibitor combination therapy.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
AU2018380132A8 (en) Tubulin inhibitors
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
MX2017000886A (en) Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene.
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12020500666A1 (en) Pladienolide compounds and their use
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.